December 1, 2014

homepage

Continue Reading
March 13, 2018

X-Chem Announces Licensing of Two Discovery Programs to AbbVie

Small molecule drug discovery specialist XChem, Inc. today announced that AbbVie has exercised options to license two discovery programs. Under the terms of the parties’ 2016 multi-target research collaboration, AbbVie had an option to an exclusive license to the programs, each of which comprises multiple novel, cell-active modulators of two historically challenging targets in oncology […]

Continue Reading
Continue Reading